Home    Back

Bertilimumab    (DrugBank: -)

2 diseases
IDDisease name (Link within this page)Number of trials
97Ulcerative colitis1
162Pemphigoid1

97. Ulcerative colitis    [ 2,269 clinical trials,   1,331 drugs,   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways]
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,269 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01671956
(ClinicalTrials.gov)		July 20159/8/2012Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative ColitisA Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study Designed to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profile of Bertilimumab in Patients With Active Moderate to Severe Ulcerative ColitisUlcerative Colitis, Active Moderate;Ulcerative Colitis, Active SevereBiological: Bertilimumab;Biological: PlaceboImmune PharmaceuticalsNULLUnknown status18 Years70 YearsAll42Phase 2Israel

162. Pemphigoid    [ 70 clinical trials,   117 drugs,   (DrugBank: 46 drugs),   30 drug target genes,   128 drug target pathways]
Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 70 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02226146
(ClinicalTrials.gov)		February 201627/7/2014Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous PemphigoidAn Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous PemphigoidPemphigoid, BullousBiological: BertilimumabImmune PharmaceuticalsNULLCompleted60 YearsN/AAll11Phase 2United States;Israel